MedStar Authors catalog › Details for: Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi()).
Normal view MARC view ISBD view

Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi()).

by Shara, Nawar M.
Citation: Journal of Foot & Ankle Surgery. 52(6):781-5, 2013 Nov-Dec..Journal: The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.ISSN: 1067-2516.Full author list: Shanmugam VK; McNish S; Shara N; Hubley KJ; Kallakury B; Dunning DM; Attinger CE; Steinberg JS.UI/PMID: 23953278.Subject(s): Antimetabolites/ae [Adverse Effects] | Chronic Disease | Enzyme Inhibitors/pd [Pharmacology] | *Enzyme Inhibitors/tu [Therapeutic Use] | Humans | Hydroxyurea/ae [Adverse Effects] | *Janus Kinases/ai [Antagonists & Inhibitors] | Leg | Male | Middle Aged | *Polycythemia Vera/co [Complications] | Pyrazoles/pd [Pharmacology] | *Pyrazoles/tu [Therapeutic Use] | Skin Transplantation | *Skin Ulcer/dt [Drug Therapy] | Skin Ulcer/su [Surgery] | *Wound Healing/de [Drug Effects] | Wounds and Injuries/dt [Drug Therapy] | Wounds and Injuries/su [Surgery]Institution(s): MedStar Health Research InstituteActivity type: Journal Article.Medline article type(s): Case Reports | Journal Article | Research Support, N.I.H., ExtramuralDigital Object Identifier: (Click here) Abbreviated citation: J Foot Ankle Surg. 52(6):781-5, 2013 Nov-Dec.Local Holdings: Available online through MWHC library: 2003 - present, Available in print through MWHC library:1999-2007.Abstract: We present the case of a 63-year-old white male with bilateral chronic leg ulcers due to polycythemia vera and hydroxyurea therapy who demonstrated dramatic healing of his wounds in response to ruxolitinib (Jakafi(), Novartis), a novel Janus kinase-1 and -2 inhibitor. This patient's wound had previously been refractory to multiple surgical interventions and immunosuppression. After the initiation of ruxolitinib, the patient underwent successful split-thickness skin grafting, with resultant healing of his wounds. He was stable without prednisone and other immunosuppressant therapy and had healed at 6 months. Ruxolitinib therapy could represent a novel option for patients who develop persistent inflammatory wounds in the setting of polycythemia vera and hydroxyurea therapy. Copyright 2013 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.

Powered by Koha